Fig. 1 · Structure

Documents & Downloads

Phenylbutazone

Cat. No. A10720 CAS 50-33-9

COX inhibitor

Phenylbutazone is a compound of research interest as an anti-inflammatory and anti-proliferative agent.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Phenylbutazone Research Summary

This section summarizes 2 in vivo studies of Phenylbutazone from 1 published reference. In vivo models include LiPan embryos/fry.

Phenylbutazone In Vivo Studies

Phenylbutazone treatment in LiPan embryos/fry produced a maximal reduction in liver RFP fluorescence of 41.1% at 1 mg/L. A statistically significant reduction in liver size was observed only at the highest phenylbutazone concentration, 1 mg/L, with a reduction of 12.1%. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Reduced Liver RFP Fluorescence in LiPan Embryos and Fry

Animal study · LiPan embryos/fry [1]

The maximal reduction of RFP fluorescence observed: 41.1% by 1 mg/L phenylbutazone.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
liver RFP intensityliver RFP intensity 1 mg/L phenylbutazone: 41.1% reduction of RFP fluorescence[1]

Conditions shared by the study groups

Route
carried out in 6-well plates
Treatment course
from 3 hpf to 120 hpf
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Phenylbutazone 0.1–1 mg/Lrespective controlsMaximal reduction of RFP fluorescence: 41.1% by 1 mg/L phenylbutazone.[1]
Phenylbutazone 0.1–1 mg/L
Model: LiPan embryos/fry
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Phenylbutazone

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Chemical Exposure to Zebrafish Fry (S6); Materials and Methods > Imaging and Data Analysis (S26); Results > Reduction of Liver Red Fluorescence and Size in LiPan Transgenic Fry by Hepatotoxins (S40, S41, S42)

liver RFP intensity: liver RFP intensity; comparator: respective controls — Results > Reduction of Liver Red Fluorescence and Size in LiPan Transgenic Fry by Hepatotoxins (S41, S42)

Phenylbutazone 0.1–1 mg/L · Materials and Methods > Chemical Exposure to Zebrafish Fry (S6); Results > Reduction of Liver Red Fluorescence and Size in LiPan Transgenic Fry by Hepatotoxins (S40, S42)

Liver Size Reduction in LiPan Embryos/Fry

Animal study · LiPan embryos/fry [1]

In LiPan embryos/fry, Phenylbutazone treatment at 1 mg/L produced a statistically significant liver size reduction of 12.1%. This reduction was observed only at the highest Phenylbutazone concentration tested.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
liver sizeliver size 12.1%[1]

Conditions shared by the study groups

Route
carried out in 6-well plates
Treatment course
from 3 hpf to 120 hpf
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Phenylbutazone 0.1–1 mg/Lrespective controlsStatistically significant reduction was observed only from the highest concentration treatments for aspirin (20 mg/L) and phenylbutazone (1 mg/L) and the reduction was 15.9% and 12.1% respectively[1]
Phenylbutazone 0.1–1 mg/L
Model: LiPan embryos/fry
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Phenylbutazone

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and Methods > Chemical Exposure to Zebrafish Fry (S6); Materials and Methods > Imaging and Data Analysis (S26); Results > Reduction of Liver Red Fluorescence and Size in LiPan Transgenic Fry by Hepatotoxins (S40, S43, S44)

liver size: liver size; comparator: respective controls — Results > Reduction of Liver Red Fluorescence and Size in LiPan Transgenic Fry by Hepatotoxins (S43, S44)

Phenylbutazone 0.1–1 mg/L · Materials and Methods > Chemical Exposure to Zebrafish Fry (S6); Results > Reduction of Liver Red Fluorescence and Size in LiPan Transgenic Fry by Hepatotoxins (S40, S44)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 50-33-9
Applications COX inhibitor
Formula C19H20N2O2
Molecular Weight 308.38
Synonyms Bute; Butatron; Butazolidin
SMILES
CCCCC1C(=O)N(N(C1=O)C2=CC=CC=C2)C3=CC=CC=C3

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 55 mg/mL (178.35 mM)
Water Insoluble
Ethanol 55 mg/mL (178.35 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Phenylbutazone Research References

  1. [1] Zhang X, Li C, Gong Z. Development of a convenient in vivo hepatotoxin assay using a transgenic zebrafish line with liver-specific DsRed expression. PLoS One (2014). PMID: 24626481 DOI: 10.1371/journal.pone.0091874 Source material

Added to your cart

View Cart Checkout
Loading...